Skip to main content
SpringerLink
Log in

Methotrexate

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

  • 641 Accesses

Abstract

Through a variety of mechanisms, including folate-independent pathways, once weekly low-dose methotrexate, either oral or parenteral, has been demonstrated to exert immune-modifying effects. For the treatment of inflammatory bowel disease, there are prospective data supporting the use of methotrexate to treat adult Crohn disease. Notably, well-designed clinical trials in ulcerative colitis did not show efficacy of this therapy. The current data in pediatric Crohn disease are largely retrospective but consistently encouraging. Large pediatric registry data clearly demonstrate that the rate of use of methotrexate in pediatric Crohn disease has risen, including its use in combination with anti-tumor necrosis factor (TNF) agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Conrad MA, Rosh JR. Pediatric inflammatory bowel disease. Pediatr Clin N Am. 2017;64:577–91.

    Google Scholar 

  2. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–35.

    CAS  PubMed  Google Scholar 

  3. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol. 2006;4:1124–9.

    CAS  PubMed  Google Scholar 

  4. Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulatory use as early therapy in pediatric Crohn disease. J Clin Gastroenterol. 2006;40:145–8.

    CAS  PubMed  Google Scholar 

  5. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology. 2000;119:895–902.

    CAS  PubMed  Google Scholar 

  6. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–58.

    CAS  PubMed  Google Scholar 

  7. Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–14.

    PubMed  Google Scholar 

  8. Panaccione R. Methotrexate: lessons from rheumatology. Can J Gastroenterol. 2005;9:541–2.

    Google Scholar 

  9. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn disease. The North American Crohn study group investigators. N Engl J Med. 1995;332:292–7.

    CAS  PubMed  Google Scholar 

  10. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn study group investigators. N Engl J Med. 2000;342:1627–32.

    CAS  PubMed  Google Scholar 

  11. Colman RJ, Lawton RC, Dubinsky MC, Rubin DT. Methotrexate for the treatment of pediatric Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018:2135–41.

    Google Scholar 

  12. Dulai PS. Methotrexate monotherapy for induction and maintenance of clinical remission in ulcerative colitis: dead on arrival. Gastroenterology. 2018;155:967–9.

    PubMed  Google Scholar 

  13. Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1243–7.

    Google Scholar 

  14. Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41:1049–60.

    CAS  PubMed  Google Scholar 

  15. Paillot R, Genestier L, Fournel S, et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc. 1998;30:2348–50.

    CAS  PubMed  Google Scholar 

  16. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247–57.

    CAS  PubMed  Google Scholar 

  17. Johnston A, Gudjonsson JE, Sigmundskottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation of adhesion molecules. Clin Immunol. 2005;114:154–63.

    CAS  PubMed  Google Scholar 

  18. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin N Am. 1997;23:739–55.

    CAS  Google Scholar 

  19. vanDieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van derWoude J. Revisiting the immunomodulators tacrolimus. Methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006;12:311–27.

    Google Scholar 

  20. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 2004;98:530–7.

    Google Scholar 

  21. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomized, investigator-blind study. Dig Liver Dis. 2003;35:619–27.

    CAS  PubMed  Google Scholar 

  22. Mate-Jimenez J, Hermida C, Canter-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227–33.

    CAS  PubMed  Google Scholar 

  23. Turner D, Grossman AB, Rosh JR, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn disease. Am J Gastrol. 2007;102:2804–12.

    CAS  Google Scholar 

  24. Turner D, Doveh E, Cohen A, Wilson ML, Grossman AB, Rosh JR, Lu Y, Bousvaros A, Deslandres C, Noble A, Baldassano RN, Levine A, Lerner A, Wilson DC, Griffiths AM. Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study. Gut. 2015;64:1898–904.

    CAS  PubMed  Google Scholar 

  25. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn disease after 6-mercaptopurine. J Pediatr. 1998;132:830–5.

    CAS  PubMed  Google Scholar 

  26. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn disease: a French multicenter study. Inflamm Bowel Dis. 2006;12:1053–7.

    CAS  PubMed  Google Scholar 

  27. Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010;51:714–7.

    CAS  PubMed  Google Scholar 

  28. Scherkenbach LA, Stumpf JL. Methotrexate for the management of Crohn’s disease in children. Ann Pharmacother. 2016;50:60–9.

    CAS  PubMed  Google Scholar 

  29. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44:427–30.

    CAS  PubMed  Google Scholar 

  30. Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009;48:526–30.

    CAS  PubMed  Google Scholar 

  31. Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis. 2011;17:2521–6.

    PubMed  Google Scholar 

  32. Sunseri W, Hyams JS, Lerer T, et al. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20:134–5.

    Google Scholar 

  33. Haisma S-M, Lijftogt T, Kindermann A, et al. Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines: a multicenter cohort study. J Crohns Colitis. 2015;9:305–11.

    PubMed  Google Scholar 

  34. Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150:380–8.

    CAS  PubMed  Google Scholar 

  35. Herfarth H, Barnes EL, Valentine JF, et al. Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018;155:1098–108.

    CAS  PubMed  Google Scholar 

  36. Aloi M, Di Nardo G, Conte F, et al. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral Centre. Aliment Pharmacol Ther. 2010;32:1017–22.

    CAS  PubMed  Google Scholar 

  37. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastro. 2018;67:257–91.

    Google Scholar 

  38. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–8.

    CAS  PubMed  Google Scholar 

  39. Narula N, Peyrin-Biroulet L, Colombel JF. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? Gastroenterology. 2014;146:608–11.

    CAS  PubMed  Google Scholar 

  40. Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1748–56.

    CAS  PubMed  Google Scholar 

  41. Vahabnezhad E, Rabizadeh S, Dubinsky MC. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:606–13.

    PubMed  Google Scholar 

  42. Colman RJ, Rubin DT. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015;9:312–7.

    PubMed  PubMed Central  Google Scholar 

  43. Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn disease. Aliment Pharmacol Ther. 2003;18:57–63.

    CAS  PubMed  Google Scholar 

  44. Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Peditr Gastroenterol Nutr. 2005;40:445–9.

    CAS  Google Scholar 

  45. Balis FM, Mirro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6:1882–6.

    CAS  PubMed  Google Scholar 

  46. Wilson A, Patel V, Chande N, Ponich T, Urquhart B, Asher L, Choi Y, Tirona R, Kim RB, Gregor JC. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37:340–5.

    CAS  PubMed  Google Scholar 

  47. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease, J Crohn’s Colitis, Volume 8, Issue 10, October 2014, Pages 1179–1207,

    Google Scholar 

  48. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr. 1992;120:468–73.

    CAS  PubMed  Google Scholar 

  49. Bulatovic M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63:2007–13.

    CAS  PubMed  Google Scholar 

  50. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn disease. Aliment Pharmacol Ther. 2001;15:35–44.

    CAS  PubMed  Google Scholar 

  51. Batres LA, Gabriel CA, Tsou VM. Methotrexate-induced esophagitis in a child with crohn disease. J Pediatr Gastroenterol Nutr. 2003;37:514–6.

    PubMed  Google Scholar 

  52. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145–56.

    PubMed  Google Scholar 

  53. Kremer JM, Alarcon GS, Lightfood RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guideline for monitoring liver toxicity. Arthritis Rheum. 1994;37:316–28.

    CAS  PubMed  Google Scholar 

  54. Khan N, Abbas AM, Whang N, Balart LA, Bazzano LA, Kelly TN. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012;18:359–67.

    PubMed  Google Scholar 

  55. Valentino PL, Church PC, Shah PS, Beyene J, Griffiths AM, Feldman BM, Kamath BM. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:47–59.

    PubMed  Google Scholar 

  56. Llaóa J, Masnouc H, Romeroa C, Bargallóc A, et al. Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate. Eur J Gastroenterol Hepatol. 2021;33:794–8.

    Google Scholar 

  57. Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995;50:137–56.

    CAS  PubMed  Google Scholar 

  58. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ. 2015;350:1269.

    Google Scholar 

  59. Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, Bramer W, van Puijenbroek E, Hazes JMW, Te Winkel B. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update. 2020;26:961–1001.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Development and Research Affairs, Goryeb Children’s Hospital/Atlantic Health, Morristown, NJ, USA

    Joel R. Rosh

  2. Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Joel R. Rosh

Authors
  1. Joel R. Rosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel R. Rosh .

Editor information

Editors and Affiliations

  1. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Petar Mamula

  2. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Judith R. Kelsen

  3. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Andrew B. Grossman

  4. Division of GI, Hepatology & Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Robert N. Baldassano

  5. Division of Pediatric Gastroenterology, Prisma Health Children’s Hospital—Upstate, Greenville, SC, USA

    Jonathan E. Markowitz

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rosh, J.R. (2023). Methotrexate. In: Mamula, P., Kelsen, J.R., Grossman, A.B., Baldassano, R.N., Markowitz, J.E. (eds) Pediatric Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-14744-9_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14744-9_30

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14743-2

  • Online ISBN: 978-3-031-14744-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation